AstraZeneca says buying Alexion will generate saving of $500m a year thanks to manufacturing and commercial synergies. AstraZeneca announced it would buy Alexion for a total consideration of $39 billion at the weekend, citing the latter’s capabilities in immunology as the primary driver for the deal. Coverage has focused on products Alexion will add to AstraZeneca’s pipeline with the monoclonal antibody-based blood disorder treatments Soliris (Eculizumab) and Ultomiris (ravulizumab) being the obvious examples. In its Q3 call Alexion said it…